Document is current

Article History

Received: 27 March 2023

Accepted: 8 August 2023

First Online: 30 September 2023

Acknowledgements

: We thank the staff and participants from the Copenhagen General Population Study for their valuable contributions. Some of the data were presented as an abstract at the European Atherosclerosis Society meeting in 2023.

: The data cannot be shared due to regulations by the Danish Data Protection Agency. However, additional analyses can be performed upon reasonable request to the corresponding author.

: We thank the Independent Research Fund Denmark (grant 1030-00168B), Novo Nordisk Foundation (grant NNF21OC0071977), Johan and Lise Boserup Fund, Aase and Ejnar Danielsen Fund and Herlev and Gentofte Hospital for providing funding. The funders had no role in the design of the study or collection, analysis, interpretation of data or in writing the manuscript.

: BGN reports consultancies and talks sponsored by AstraZeneca, Sanofi, Regeneron, Akcea, Ionis, Amgen, Kowa, Denka, Amarin, Novartis, Novo Nordisk, Esperion, Abbott and Silence Therapeutics. There are no competing interests for BNW, KMP or ABW.

: BNW planned and performed statistical analyses and wrote first draft of the paper. KMP, ABW and BGN revised the paper for critical scientific content, as well provided substantial support in the statistical analysis, and interpretation of the results. KMP independently verified key results. BGN defined the research topic jointly with the other authors. All authors read and approved the final manuscript. BNW and BGN are responsible for the integrity of the work as a whole.